Clinical Trials Directory

Trials / Completed

CompletedNCT01079832

Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies

A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Case Comprehensive Cancer Center · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This clinical trial studies stereotactic radiosurgery using CyberKnife works in treating women with advanced or recurrent gynecological malignancies.

Detailed description

PRIMARY OBJECTIVES: I. The primary goal of this study is to estimate the rate of grade 3 or higher acute toxicities observed during a 6 month period following CyberKnife radiosurgery for gynecologic cancers. II. To evaluate clinical response to radio-surgery for gynecologic tumors. III. To assess general and site specific quality of life (using SF-12, FACT-En, FACT-O, FACT-Cx or FACT-V) and to evaluate patient's level of pain. SECONDARY OBJECTIVES: I. As a secondary objective, toxicities during the 2 years following CyberKnife radiosurgery will also be described. OUTLINE: Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery. After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.

Conditions

Interventions

TypeNameDescription
RADIATIONstereotactic radiosurgeryRadiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
PROCEDUREquality-of-life assessmentAncillary studies

Timeline

Start date
2009-05-01
Primary completion
2012-05-01
Completion
2012-05-01
First posted
2010-03-03
Last updated
2013-11-28
Results posted
2013-11-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01079832. Inclusion in this directory is not an endorsement.